Novel theranostic agent targets multiple cancer types
A newly discovered radionuclide-based agent (CB-2PA-NT) has been shown to have high tumour uptake, sustained…
A newly discovered radionuclide-based agent (CB-2PA-NT) has been shown to have high tumour uptake, sustained…
The SYMPLIFY study is the first large-scale evaluation of a multi-cancer early detection (MCED) test in individuals…
While the incidence of colorectal cancer (CRC) has dropped significantly among older adults in recent…
A phase 3 trial has demonstrated that patients with advanced stage (3 or 4) classic Hodgkin lymphoma…
Historically, surgery was the first line of treatment for patients with thyroid cancer. Now, as…
In a phase 2 clinical trial of the immune checkpoint inhibitor pembrolizumab, investigators found that…
MIRASOL, an international phase III randomised clinical trial, found that mirvetuximab soravtansine, an antibody and…
Trastuzumab deruxtecan (marketed as Enhertu) is an effective treatment option for people with difficult-to-treat HER2-expressing…
“We’ve reached a tipping point in treating patients with rectal cancer. As we develop new…
Australia is riding a wave of emerging innovative and ground-breaking diagnostic technologies and cancer treatments…